Cookies

We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content. For more information, visit our privacy policy. By clicking “accept" or continuing to browse this website without disabling cookies, you consent to the use of cookies.

Cookie Settings
Container image

A Robust Portfolio of Prototype Assays

Product Overview

The NTK offers a portfolio of exploratory prototype assays designed to generate high quality, comparable clinical biomarker data across academic and industry cohorts. The NTK assays can be run on the fully automated Cobas® platform in four NTK qualified labs. This ensures that high quality, reproducible data can be compared with multiple datasets - maximizing how results can be interpreted. This clarifies the clinical utility of biomarkers, how they can be used in clinical trials, and ultimately which biomarkers warrant further development for use in routine clinical practice.

*The NTK is only for basic research or the initial search for potential clinical utility. The measurements must not be used to make any medical decisions.

 

NTK Hackathon tables
Container image

The power of Elecsys® in Alzheimer's disease

Robust and accurate biomarker tests to solve clinical questions

  • Elecsys® assays achieve highly accurate and precise results across all Cobas® platforms, with the precision being confirmed in the Alzheimer's Association Quality Control (AAQC) program;
  • Elecsys® assays show robust reagent and calibration stability.

AAQC results (2014-2020)

The green box and whiskers plots are manual assay results, and the blue ones are automated assay results.

Biomarker: β-amyloid (1-42)

This box and whisker plot shows the coefficient of variation (in %) from the AAQC rounds (years 2014-2020). The variability is far lower with automated platforms (depicted in blue) than manual platforms (depicted in green).

COBAS, COBAS E and ELECSYS are trademarks of Roche